Jubilant Pharmova Limited (JUBLPHARMA.BO)
INR 881.1
(-0.37%)
INR 881.1
(-0.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 771 Million INR | 226.43% |
| 2022 | -609.8 Million INR | -114.73% |
| 2021 | 4.13 Billion INR | -50.48% |
| 2020 | 8.35 Billion INR | -6.94% |
| 2019 | 8.98 Billion INR | 56.36% |
| 2018 | 5.74 Billion INR | -10.63% |
| 2017 | 6.42 Billion INR | 11.67% |
| 2016 | 5.75 Billion INR | 46.91% |
| 2015 | 3.91 Billion INR | 778.33% |
| 2014 | -577.64 Million INR | -152.98% |
| 2013 | 1.09 Billion INR | -28.6% |
| 2012 | 1.52 Billion INR | 948.88% |
| 2011 | 145.61 Million INR | -93.66% |
| 2010 | 2.29 Billion INR | -45.49% |
| 2009 | 4.21 Billion INR | 48.83% |
| 2008 | 2.83 Billion INR | -29.29% |
| 2007 | 4 Billion INR | 75.66% |
| 2006 | 2.28 Billion INR | 75.82% |
| 2005 | 1.29 Billion INR | 8.79% |
| 2004 | 1.19 Billion INR | 52.35% |
| 2003 | 782.37 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.02 Billion INR | -78.68% |
| 2024 Q1 | 4.82 Billion INR | 922.7% |
| 2023 FY | 771 Million INR | 226.43% |
| 2023 Q4 | -586 Million INR | -187.72% |
| 2023 Q2 | 625 Million INR | 876.56% |
| 2023 Q1 | 64 Million INR | 106.54% |
| 2023 Q3 | 668 Million INR | 6.88% |
| 2022 Q3 | -156 Million INR | -388.89% |
| 2022 Q4 | -978.4 Million INR | -527.18% |
| 2022 FY | -609.8 Million INR | -114.73% |
| 2022 Q1 | 471 Million INR | -20.9% |
| 2022 Q2 | 54 Million INR | -88.54% |
| 2021 Q1 | 1.6 Billion INR | -24.94% |
| 2021 FY | 4.13 Billion INR | -50.48% |
| 2021 Q2 | 1.42 Billion INR | -11.04% |
| 2021 Q3 | 509.9 Million INR | -64.3% |
| 2021 Q4 | 595.46 Million INR | 16.78% |
| 2020 Q2 | 2.24 Billion INR | 154.55% |
| 2020 Q1 | 880.1 Million INR | -66.21% |
| 2020 Q3 | 3.09 Billion INR | 38.34% |
| 2020 Q4 | 2.13 Billion INR | -30.98% |
| 2020 FY | 8.35 Billion INR | -6.94% |
| 2019 Q4 | 2.6 Billion INR | 28.08% |
| 2019 Q2 | 2.49 Billion INR | 34.82% |
| 2019 Q1 | 1.84 Billion INR | 286.3% |
| 2019 Q3 | 2.03 Billion INR | -18.45% |
| 2019 FY | 8.98 Billion INR | 56.36% |
| 2018 Q4 | -992.94 Million INR | -138.07% |
| 2018 Q3 | 2.6 Billion INR | 23.97% |
| 2018 Q2 | 2.1 Billion INR | 3.91% |
| 2018 FY | 5.74 Billion INR | -10.63% |
| 2018 Q1 | 2.02 Billion INR | 30.75% |
| 2017 Q4 | 1.54 Billion INR | -27.13% |
| 2017 Q3 | 2.12 Billion INR | 65.71% |
| 2017 Q2 | 1.28 Billion INR | -12.83% |
| 2017 FY | 6.42 Billion INR | 11.67% |
| 2017 Q1 | 1.47 Billion INR | -1.99% |
| 2016 Q2 | 1.43 Billion INR | -12.42% |
| 2016 Q1 | 1.63 Billion INR | 1409.39% |
| 2016 FY | 5.75 Billion INR | 46.91% |
| 2016 Q3 | 1.18 Billion INR | -17.73% |
| 2016 Q4 | 1.5 Billion INR | 27.11% |
| 2015 FY | 3.91 Billion INR | 778.33% |
| 2015 Q4 | 108.6 Million INR | -91.17% |
| 2015 Q3 | 1.23 Billion INR | -1.43% |
| 2015 Q2 | 1.24 Billion INR | -5.4% |
| 2015 Q1 | 1.31 Billion INR | 208.78% |
| 2014 Q4 | 427.26 Million INR | 482.85% |
| 2014 FY | -577.64 Million INR | -152.98% |
| 2014 Q1 | 47.8 Million INR | -95.16% |
| 2014 Q2 | -941.1 Million INR | -2068.83% |
| 2014 Q3 | -111.6 Million INR | 88.14% |
| 2013 Q4 | 988.1 Million INR | -31.11% |
| 2013 FY | 1.09 Billion INR | -28.6% |
| 2013 Q2 | -805.8 Million INR | -53.14% |
| 2013 Q1 | -526.2 Million INR | -69.89% |
| 2013 Q3 | 1.43 Billion INR | 278.0% |
| 2012 Q1 | -9.08 Billion INR | -1329.5% |
| 2012 Q3 | 266.9 Million INR | -82.44% |
| 2012 FY | 1.52 Billion INR | 948.88% |
| 2012 Q2 | 1.52 Billion INR | 116.74% |
| 2012 Q4 | -309.73 Million INR | -216.05% |
| 2011 Q4 | -635.29 Million INR | 18.96% |
| 2011 Q3 | -783.9 Million INR | 0.0% |
| 2011 FY | 145.61 Million INR | -93.66% |
| 2010 FY | 2.29 Billion INR | -45.49% |
| 2009 FY | 4.21 Billion INR | 48.83% |
| 2008 FY | 2.83 Billion INR | -29.29% |
| 2007 FY | 4 Billion INR | 75.66% |
| 2006 FY | 2.28 Billion INR | 75.82% |
| 2005 FY | 1.29 Billion INR | 8.79% |
| 2004 FY | 1.19 Billion INR | 52.35% |
| 2003 FY | 782.37 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 87.48% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 97.57% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 83.627% |
| Granules India Limited | 4.05 Billion INR | 80.978% |
| Indoco Remedies Limited | 984.6 Million INR | 21.694% |
| Achyut Healthcare Limited | 5.73 Million INR | -13350.803% |
| Ajanta Pharma Limited | 8.16 Billion INR | 90.553% |
| Alkem Laboratories Limited | 17.95 Billion INR | 95.707% |
| Alpa Laboratories Limited | 167.76 Million INR | -359.571% |
| Brooks Laboratories Limited | -195.91 Million INR | 493.53% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 52.263% |
| Bajaj HealthCare Limited | -837.93 Million INR | 192.012% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -2.181% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 98.615% |
| Eris Lifesciences Limited | 3.91 Billion INR | 80.331% |
| FDC Limited | 3.05 Billion INR | 74.74% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 105.134% |
| Gufic Biosciences Limited | 861.35 Million INR | 10.49% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 81.685% |
| Ipca Laboratories Limited | 5.47 Billion INR | 85.914% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -243.231% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 490.807% |
| Lasa Supergenerics Limited | -217.3 Million INR | 454.799% |
| Laurus Labs Limited | 1.6 Billion INR | 51.978% |
| Lupin Limited | 19.14 Billion INR | 95.973% |
| Mankind Pharma Limited | 19.12 Billion INR | 95.969% |
| Medicamen Biotech Limited | 109.31 Million INR | -605.333% |
| Medico Remedies Limited | 82.9 Million INR | -829.935% |
| Megasoft Limited | -127.46 Million INR | 704.867% |
| NATCO Pharma Limited | 13.88 Billion INR | 94.446% |
| Piramal Pharma Limited | 178.2 Million INR | -332.66% |
| RPG Life Sciences Limited | 876.6 Million INR | 12.047% |
| Sigachi Industries Limited | 571.8 Million INR | -34.837% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.195% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 74.324% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -204.572% |
| Unichem Laboratories Limited | -704.74 Million INR | 209.402% |
| Wanbury Limited | 559.56 Million INR | -37.786% |
| Windlas Biotech Limited | 581.87 Million INR | -32.504% |
| ZIM Laboratories Limited | 172.46 Million INR | -347.05% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 98.002% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 119.911% |
| Divi's Laboratories Limited | 16 Billion INR | 95.181% |
| Hester Biosciences Limited | 188.89 Million INR | -308.174% |
| Procter & Gamble Health Limited | 2 Billion INR | 61.638% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -71.438% |
| Bal Pharma Limited | 73.92 Million INR | -942.991% |
| Strides Pharma Science Limited | -706.14 Million INR | 209.185% |
| Venus Remedies Limited | 284.9 Million INR | -170.614% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 64.454% |
| Nectar Lifesciences Limited | 49.95 Million INR | -1443.544% |
| Shilpa Medicare Limited | 318.74 Million INR | -141.888% |
| Aarti Drugs Limited | 1.71 Billion INR | 55.022% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 42.647% |
| Suven Life Sciences Limited | -1.05 Billion INR | 173.375% |
| Ind-Swift Limited | 142.31 Million INR | -441.764% |
| Valiant Laboratories Limited | 3.19 Million INR | -24023.905% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 86.048% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 113.589% |
| Themis Medicare Limited | 435.23 Million INR | -77.144% |
| Hikal Limited | 696.02 Million INR | -10.773% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 95.345% |
| Sequent Scientific Limited | -358.69 Million INR | 314.949% |
| Novartis India Limited | 851.9 Million INR | 9.496% |
| Wockhardt Limited | -4.63 Billion INR | 116.652% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -10771.404% |
| Neuland Laboratories Limited | 3 Billion INR | 74.307% |
| Morepen Laboratories Limited | 961.59 Million INR | 19.821% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -428.032% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 949.896% |